2021年至2023年期间，比利时通过接种COVID-19疫苗避免了死亡

IF 4.5 3区医学 Q2 IMMUNOLOGY

Vaccine Pub Date : 2025-05-30 DOI:10.1016/j.vaccine.2025.127290

Veerle Stouten , Izaak Van Evercooren , Catharina Vernemmen , Toon Braeye , Lucy Catteau , Mathieu Roelants , Matthieu Billuart , Thomas Lamot , Natalia Bustos Sierra , Naïma Hammami , Elias Vermeiren , Angel Rosas , Koen Blot , Anna I. Schmelz , Léonore Nasiadka , Serge Nganda , Joris A.F. van Loenhout

{"title":"2021年至2023年期间，比利时通过接种COVID-19疫苗避免了死亡","authors":"Veerle Stouten , Izaak Van Evercooren , Catharina Vernemmen , Toon Braeye , Lucy Catteau , Mathieu Roelants , Matthieu Billuart , Thomas Lamot , Natalia Bustos Sierra , Naïma Hammami , Elias Vermeiren , Angel Rosas , Koen Blot , Anna I. Schmelz , Léonore Nasiadka , Serge Nganda , Joris A.F. van Loenhout","doi":"10.1016/j.vaccine.2025.127290","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Vaccination campaigns were rolled out primarily to limit the impact of COVID-19 on severe health outcomes, including mortality.</div></div><div><h3>Aim</h3><div>We aimed to estimate the number of averted deaths by COVID-19 vaccination in the Belgian population aged 65 years and older, between January 2021 and January 2023.</div></div><div><h3>Methods</h3><div>Nationwide data on COVID-19 infections, vaccine administrations and all-cause mortality were individually linked. We estimated Vaccine Effectiveness against COVID-19 mortality (VE) among persons having received a vaccine dose in the last 6 months, using a Cox proportional hazards model adjusted for age, sex, time since vaccination, previous infection, underlying health conditions, province and income. COVID-19 death was defined as a person with a laboratory-confirmed SARS-CoV-2 infection who died within a specified interval. Based on obtained VE estimates, vaccine coverage and national COVID-19 mortality data, we estimated the number of averted deaths.</div></div><div><h3>Results</h3><div>We estimated VE (confidence interval (CI)) at 0–59 days after vaccination, for 65–79 year and ≥ 80 year-olds respectively, at 81.9 % (CI 78.1 %–85.1 %) and 74.7 % (CI 71.2 %–77.7 %) during Alpha, at 90.5 % (CI 88.8 %–91.9 %) and 91.4 % (CI 90.4 %–92.4 %) during Delta and at 84.0 % (CI 81.8 %–85.9 %) and 74.5 % (CI 72.4 %–76.5 %) during Omicron period. Among the Belgian population aged 65 years and older, we estimated 12,806 deaths averted (CI 11,633-13,982), representing a 54 % reduction (CI 51 %–56 %) in the expected deaths (without vaccination). During the Delta period COVID-19 deaths were reduced by 68 %, during Omicron by 54 % and during Alpha by 31 %.</div></div><div><h3>Discussion</h3><div>Vaccinating against COVID-19 reduced deaths by 54 % among the Belgian population aged 65 years and older, underscoring the importance of COVID-19 vaccines in reducing mortality.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"60 ","pages":"Article 127290"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023\",\"authors\":\"Veerle Stouten , Izaak Van Evercooren , Catharina Vernemmen , Toon Braeye , Lucy Catteau , Mathieu Roelants , Matthieu Billuart , Thomas Lamot , Natalia Bustos Sierra , Naïma Hammami , Elias Vermeiren , Angel Rosas , Koen Blot , Anna I. Schmelz , Léonore Nasiadka , Serge Nganda , Joris A.F. van Loenhout\",\"doi\":\"10.1016/j.vaccine.2025.127290\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Vaccination campaigns were rolled out primarily to limit the impact of COVID-19 on severe health outcomes, including mortality.</div></div><div><h3>Aim</h3><div>We aimed to estimate the number of averted deaths by COVID-19 vaccination in the Belgian population aged 65 years and older, between January 2021 and January 2023.</div></div><div><h3>Methods</h3><div>Nationwide data on COVID-19 infections, vaccine administrations and all-cause mortality were individually linked. We estimated Vaccine Effectiveness against COVID-19 mortality (VE) among persons having received a vaccine dose in the last 6 months, using a Cox proportional hazards model adjusted for age, sex, time since vaccination, previous infection, underlying health conditions, province and income. COVID-19 death was defined as a person with a laboratory-confirmed SARS-CoV-2 infection who died within a specified interval. Based on obtained VE estimates, vaccine coverage and national COVID-19 mortality data, we estimated the number of averted deaths.</div></div><div><h3>Results</h3><div>We estimated VE (confidence interval (CI)) at 0–59 days after vaccination, for 65–79 year and ≥ 80 year-olds respectively, at 81.9 % (CI 78.1 %–85.1 %) and 74.7 % (CI 71.2 %–77.7 %) during Alpha, at 90.5 % (CI 88.8 %–91.9 %) and 91.4 % (CI 90.4 %–92.4 %) during Delta and at 84.0 % (CI 81.8 %–85.9 %) and 74.5 % (CI 72.4 %–76.5 %) during Omicron period. Among the Belgian population aged 65 years and older, we estimated 12,806 deaths averted (CI 11,633-13,982), representing a 54 % reduction (CI 51 %–56 %) in the expected deaths (without vaccination). During the Delta period COVID-19 deaths were reduced by 68 %, during Omicron by 54 % and during Alpha by 31 %.</div></div><div><h3>Discussion</h3><div>Vaccinating against COVID-19 reduced deaths by 54 % among the Belgian population aged 65 years and older, underscoring the importance of COVID-19 vaccines in reducing mortality.</div></div>\",\"PeriodicalId\":23491,\"journal\":{\"name\":\"Vaccine\",\"volume\":\"60 \",\"pages\":\"Article 127290\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0264410X25005870\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25005870","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

开展疫苗接种运动主要是为了限制COVID-19对严重健康后果（包括死亡率）的影响。AimWe旨在估计2021年1月至2023年1月期间比利时65岁及以上人口中通过COVID-19疫苗避免的死亡人数。方法将全国COVID-19感染、疫苗接种和全因死亡率数据单独关联。我们使用Cox比例风险模型，对年龄、性别、接种疫苗后的时间、既往感染、潜在健康状况、省份和收入进行了调整，估计了过去6个月内接种过疫苗的人的COVID-19疫苗有效性死亡率（VE）。COVID-19死亡被定义为实验室确诊的SARS-CoV-2感染患者在特定时间间隔内死亡。根据获得的VE估计值、疫苗覆盖率和国家COVID-19死亡率数据，我们估计了避免死亡的数量。结果在接种疫苗后0-59天，65-79岁和≥80岁的人群中，我们分别估计VE（置信区间（CI））在Alpha期间为81.9% （CI 78.1% - 85.1%）和74.7% (CI 71.2% - 77.7%)，在Delta期间为90.5% （CI 88.8% - 91.9%）和91.4% (CI 90.4% - 92.4%)，在Omicron期间为84.0% （CI 81.8% - 85.9%）和74.5% （CI 72.4% - 76.5%）。在比利时65岁及以上的人口中，我们估计避免了12,806例死亡（CI 11,633-13,982），表示预期死亡（未接种疫苗）减少了54% （CI 51% - 56%）。在“德尔塔”期间，COVID-19死亡人数减少了68%，“欧米克隆”期间减少了54%，“阿尔法”期间减少了31%。在比利时，接种COVID-19疫苗使65岁及以上人口的死亡率降低了54%，这凸显了COVID-19疫苗在降低死亡率方面的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Averted mortality by COVID-19 vaccination in Belgium between 2021 and 2023

Background

Vaccination campaigns were rolled out primarily to limit the impact of COVID-19 on severe health outcomes, including mortality.

Aim

We aimed to estimate the number of averted deaths by COVID-19 vaccination in the Belgian population aged 65 years and older, between January 2021 and January 2023.

Methods

Nationwide data on COVID-19 infections, vaccine administrations and all-cause mortality were individually linked. We estimated Vaccine Effectiveness against COVID-19 mortality (VE) among persons having received a vaccine dose in the last 6 months, using a Cox proportional hazards model adjusted for age, sex, time since vaccination, previous infection, underlying health conditions, province and income. COVID-19 death was defined as a person with a laboratory-confirmed SARS-CoV-2 infection who died within a specified interval. Based on obtained VE estimates, vaccine coverage and national COVID-19 mortality data, we estimated the number of averted deaths.

Results

We estimated VE (confidence interval (CI)) at 0–59 days after vaccination, for 65–79 year and ≥ 80 year-olds respectively, at 81.9 % (CI 78.1 %–85.1 %) and 74.7 % (CI 71.2 %–77.7 %) during Alpha, at 90.5 % (CI 88.8 %–91.9 %) and 91.4 % (CI 90.4 %–92.4 %) during Delta and at 84.0 % (CI 81.8 %–85.9 %) and 74.5 % (CI 72.4 %–76.5 %) during Omicron period. Among the Belgian population aged 65 years and older, we estimated 12,806 deaths averted (CI 11,633-13,982), representing a 54 % reduction (CI 51 %–56 %) in the expected deaths (without vaccination). During the Delta period COVID-19 deaths were reduced by 68 %, during Omicron by 54 % and during Alpha by 31 %.

Discussion

Vaccinating against COVID-19 reduced deaths by 54 % among the Belgian population aged 65 years and older, underscoring the importance of COVID-19 vaccines in reducing mortality.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vaccine 医学-免疫学

CiteScore

8.70

自引率

5.50%

发文量

992

审稿时长

131 days

期刊介绍： Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.